<DOC>
	<DOCNO>NCT01575275</DOCNO>
	<brief_summary>The purpose study investigate safety performance investigational agent , know 5-ALA Gliolan ( aminolevulinic acid ) , many useful surgeon visualize tumor surgery . It also study determine difference Gliolan show surgeon compare intraoperative magnetic resonance imaging ( MRI )</brief_summary>
	<brief_title>Aminolevulinic Acid Visualizing Tumor During Surgery Patients With Glioblastoma Multiforme</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine volume residual enhance tumor 5-ALA guided resection glioblastoma multiforme ( GBM ) . II . Determine volume tissue remove compare measured enhance tumor evaluate pre-operative MRI . SECONDARY OBJECTIVES : I . Evaluate time tumor progression . II . Evaluate overall survival . OUTLINE : Patients receive aminolevulinic acid orally ( PO ) 2-4 hour surgery . After completion study treatment , patient follow 2 week .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Patients must suspect biopsy proven newly diagnose GBM , recurrent GBM suspect GBM ( patient pathologically diagnose prior World Health Organization [ WHO ] grade II III tumor ) patient undergo clinicallyindicated surgery . Age &gt; = 18 year age . Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 ( Karnofsky &gt; = 60 % ) Life expectancy consideration protocol entry Patients must normal organ marrow function define : Absolute neutrophil count &gt; = 1,500/uL Platelets &gt; = 100,000/uL Total bilirubin within normal institutional limit Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamic pyruvate transaminase [ SGPT ] ) = &lt; 2.5 x institutional upper limit normal Creatinine within normal institutional limit ; OR Creatinine clearance &gt; = 60 mL/min/1.73 m^2 patient creatinine level institutional normal Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document parent guardian ability understand willingness sign write informed consent Prior therapy exclusion criterion Patients may receive investigational agent History allergic reaction attribute aminolevulinic acid ( ALA ) Current treatment hypericin ( extract ) photosensitize agent Personal immediate family ( parent , sibling , child ) history porphyria Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treat ALA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>